Performance evaluation of direct fluorescent antibody, Focus Diagnostics Simplexa™ Flu A/B & RSV and multi-parameter customized respiratory Taqman® array card in immunocompromised patients.

•Limited sensitivity of direct fluorescent antibody testing in comparison to molecular methods.•Simplexa™ direct assay is sensitive and specific for the detection of Flu A, B and RSV.•Performing the TAC would increase the diagnostic yield and detection of co-infections significantly.•Immunocompromised patient population with overall positivity rate of 62%.•Co-infection rate of 15.3% found by TAC.